CDH1突变携带者全胃切除术指征与风险降低性微创及开放胃切除术结局
这项单机构队列研究纳入181例CDH1胚系变异携带者,其中165例为致病或可能致病变异,101例接受开放或微创全胃切除术。结果显示,有胃癌家族史者手术标本中印戒细胞癌检出率89%,无家族史者为67%;微创手术淋巴结检出更多且住院时间更短。结论认为,致病或可能致病CDH1变异且有胃或小叶乳腺癌家族史者可能需要全胃切除术,无家族史者也可考虑。
要点
- 致病或可能致病CDH1变异且有胃或小叶乳腺癌家族史者,可考虑全胃切除术。
- 无家族史者手术标本中印戒细胞癌检出率仍达67%(4/6),提示也可考虑手术。
- 微创全胃切除术淋巴结检出更多且住院时间更短,对选定患者可行且可能更优。
核心结论
- 致病或可能致病CDH1变异且有胃或小叶乳腺癌家族史者可能需要全胃切除术,无家族史者也可考虑。
- 微创入路可行,对选定患者可能更优。
研究设计与样本
- 单机构队列研究,2006年1月1日至2020年1月1日,纳入181例CDH1胚系变异患者。
- 平均(SD)检测年龄44(15)岁,126例(70%)为女性;165例携带致病或可能致病变异。
- 其中101例接受开放(n=58)或微创(n=43)全胃切除术。
主要发现
- 需要引流的吻合口漏少见(n=3),长期体重下降中位数为20%(IQR 10%-23%)。
- 微创手术淋巴结检出中位数28枚(IQR 20-34)多于开放手术15枚(IQR 9-19),P<.001。
- 微创手术住院时间中位数6天(IQR 5-7)比开放手术7天(IQR 6-7)缩短1天,P=.04。
- 有胃癌家族史者手术标本中印戒细胞癌检出85/95例(89%),无家族史者4/6例(67%)。
- 无家族史6例中4例有个人或家族小叶乳腺癌史,其中2例检出印戒细胞癌;16例局部进展或转移性胃癌中3例(19%)无胃癌家族史且无小叶乳腺癌个人或家族史。
关键数值与推荐
- 致病或可能致病CDH1变异且伴胃或小叶乳腺癌家族史者,可考虑全胃切除术。
- 致病或可能致病CDH1变异但无家族史者,全胃切除术也可能合适。
- 对选定患者,微创全胃切除术可行且可能优先选择。
临床怎么用
- 对致病或可能致病CDH1变异者应进行遗传咨询和食管胃十二指肠镜评估,结合家族史讨论全胃切除术。
- 无胃癌家族史但有小叶乳腺癌个人或家族史者,仍需警惕印戒细胞癌风险。
- 选定患者行微创全胃切除术可获得更充分的淋巴结清扫和更短住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: CDH1 variants are increasingly identified on commercially available multigene panel tests, calling for data to inform counseling of individuals without a family history of gastric cancer. OBJECTIVES: To assess association between CDH1 variant pathogenicity or family history of gastric or lobular breast cancer and identification of signet ring cell cancer and to describe outcomes of risk-reducing minimally invasive and open total gastrectomy. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was performed from January 1, 2006, to January 1, 2020, in 181 patients with CDH1 germline variants from a single institution. INTERVENTIONS: Genetic counseling, esophagogastroduodenoscopy, and possible total gastrectomy. MAIN OUTCOMES AND MEASURES: CDH1 variant classification, family cancer history, findings of signet ring cell carcinoma at esophagogastroduodenoscopy and surgery, postoperative events and weight changes, and follow-up. RESULTS: Of 181 individuals with CDH1 germline variants (mean [SD] age at time of testing, 44 [15] years; 126 [70%] female), 165 harbored a pathogenic or likely pathogenic variant. Of these patients, 101 underwent open (n = 58) or minimally invasive (n = 43) total gastrectomy. Anastomotic leaks that required drainage were infrequent (n = 3), and median long-term weight loss was 20% (interquartile range [IQR], 10%-23%). In those undergoing minimally invasive operations, more lymph nodes were retrieved (median, 28 [IQR, 20-34] vs 15 [IQR, 9-19]; P < .001) and the hospital stay was 1 day shorter (median, 6 [IQR, 5-7] vs 7 [IQR, 6-7] days; P = .04). Signet ring cell cancer was identified in the surgical specimens of 85 of 95 patients (89%) with a family history of gastric cancer and 4 of 6 patients (67%) who lacked a family history. Among the latter 6 patients, 4 had a personal or family history of lobular breast cancer, including 2 with signet ring cell cancer. Of the 16 patients with pathogenic or likely pathogenic CDH1 variants who presented with locally advanced or metastatic gastric cancer, 3 (19%) had no family history of gastric cancer or personal or family history of lobular breast cancer. CONCLUSIONS AND RELEVANCE: Total gastrectomy may be warranted for patients with pathogenic or likely pathogenic CDH1 variants and a family history of gastric or lobular breast cancer and may be appropriate for those without a family history. A minimally invasive approach is feasible and may be preferred for selected patients.
引用
- Vos EL, Salo-Mullen EE, Tang LH, et al. Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surg. 2020. PMID: 32997132. doi:10.1001/jamasurg.2020.3356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。